Current Clinical Trials
You may be eligible to take part in one of the many clinical trials underway at the UCI Alpha Stem Cell Clinic. By participating in a clinical trial, patients have access to leading-edge treatments and therapies long before they are available to the general public.
The more you know about clinical trials, the better informed you will be when deciding whether to participate in a specific trial. Click on the get more information buttons to see trial specifics on the Center for Clinical Trials website.
The UCI Center for Clinical Research oversees clinical trials for UCI Health and the UCI School of Medicine. Trials cover the full spectrum of conditions, from heart disease, neurological disorders, visual impairment, and more. Please visit the center's website to search for open clinical trials.
Questions or comments? Email us at alphaclinic@uci.edu
Aspen Neurosciences Developing a Trial Ready Cohort of Parkinson Disease Patients – PI: Nicolas Phielippp
Nicolas Phielipp, M.D.
Cabaletta Bio, Inc. Phase 1 MuSK-CAART for Subjects with Anti-MuSK Antibody Positive MG
Ali Habib, M.D.
AskBio Glial Cell Line-Derived Neurotrophic Factor Gene Transfer in Multiple System Atrophy
Nicolas Phielipp, M.D.
Audentes FORTIS Gene Transfer Study in Patients with Late Onset Pompe Disease
Tahseen Mozaffar, M.D.
Cartesian Descartes-08 Generalized Myasthenia Gravis Clinical Trial
Tahseen Mozaffar, M.D.
Immunis, Inc. Open Label Use of IMM01-STEM in Patients with Muscle Atrophy Related to Knee Osteoarthritis
Dean Wang, M.D.
Regeneron Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in patients with symptomatic generalized Myasthenia Gravis
Ali Habib, M.D.
Sangamo ST-920 A Gene Therapy in Subjects with Fabry Disease
Madeleine Pahl, M.D.
Direct Biologics, Evaluating the Efficacy of EXOFLO in Treating Moderate to Severe ARDS Caused by COVID-19
Alpesh Amin, M.D.
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Dr. Nicolas Phielipp, M.D.
Safety and efficacy of LION-101 in subjects (ages 5-65) with LGMD2I/R9 impacting FKRP
Dr. Tahseen Mozaffar, M.D.
Study Evaluating Variability, Reliability, and Compliance for the Parkinson's Disease Diary
Dr. Claire Henchcliffe, M.D.
Evaluate the Safety & Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy
Tahseen Mozaffar, M.D.